Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.27 | N/A | +3.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.27 | N/A | +3.33% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Overall, management expressed a cautious outlook, acknowledging industry challenges while reaffirming their focus on product development.
Management highlighted ongoing challenges in the market.
They emphasized their commitment to innovation despite current pressures.
Amgen's earnings report showed a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock fell by 1.6% following the announcement, likely due to the lack of revenue information and no updated guidance. Investors may be concerned about the company's future performance given the current market challenges mentioned by management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STATE STR CORP
Oct 23, 2017